Discovery of tetrahydroisoquinoline-based bivalent heterodimeric IAP antagonists
Graphical abstract
References and notes (32)
- et al.
Cell Death Differ.
(2009) - et al.
Cell
(2000)et al.Cell
(2000) - et al.
J. Med. Chem.
(2004)et al.Nat. Rev.
(2012) - et al.
Nature
(2009) - et al.
J. Am. Chem. Soc.
(2009) - et al.
Synth. Commun.
(1993)et al.Tetrahedron Lett.
(1993) - et al.
Chem. Biol.
(2003) - et al.
Expert Opin. Drug Deliv.
(2010) Science
(1995)et al.Cell
(2011)- et al.
Nat. Rev. Drug Disc.
(2012)Ann. Rep. Med. Chem.
(2011)
Nat. Rev. Mol. Cell Biol.
Genes Dev.
J. Biol. Chem.
EMBO Rep.
Biochemistry
Nature
Bioorg. Med. Chem.
Cited by (14)
Targeting estrogen receptor α for degradation with PROTACs: A promising approach to overcome endocrine resistance
2020, European Journal of Medicinal ChemistryCitation Excerpt :All examples shown in Fig. 14 possess ERα degradation activity at 1 μM concentration. In 2016, GSK patented the other kind of PROTAC compounds incorporating IAP recruiting moiety [140] and raloxifene derivative [141,142]. These PROTACs displayed >50% ERα degradation at concentrations lower than 1 μM (Fig. 15).
Mapping the substrate scope of monoamine oxidase (MAO-N) as a synthetic tool for the enantioselective synthesis of chiral amines
2018, Bioorganic and Medicinal ChemistryCitation Excerpt :A variety of strategies such as diastereomeric resolution, homogeneous catalysis or biocatalytic approaches have been reported for the preparation of chiral amines.7 The use of biocatalysis has grown remarkably in the past decades as exemplified by the use of ω-transaminases,8 phenylalanine ammonia lyases,9 amine dehydrogenases10 and imine reductases.11 An attractive alternative to the kinetic resolution of amines involves the use of monoamine oxidase, an enzyme class which only requires aerial oxygen with no need for additional or sacrificial co-factors.12
Building homogeneous time-resolved fluorescence resonance energy transfer assays for characterization of bivalent inhibitors of an inhibitor of apoptosis protein target
2016, Analytical BiochemistryCitation Excerpt :Bivalent Smac-mimetic ligands are expected to mimic the mode of action of the mature dimeric Smac protein in its interaction with XIAP. Thus, it is not surprising that, in our current and previous studies [17,18,23], bivalent Smac-mimetics that bind concurrently to both the BIR2 and BIR3 domains of XIAP achieve much higher affinities than do the corresponding monovalent analogs. Bivalent Smac-based ligands were also much more potent antagonists of XIAP compared with the corresponding monovalent Smac-based ligands in cell proliferation and cell-free caspase functional assays.
Pharmacology of smac mimetics; chemotype differentiation based on physical association with caspase regulators and cellular transport
2015, Experimental Cell ResearchCitation Excerpt :Inhibition data was calculated from average reaction rate values generated by using a proprietary XIAP BIR2-3 antagonist at 20 µM and a vehicle-only reaction for 100% and 0% inhibition respectively Assays were performed in 96 well plates as described [32]. Briefly, cells were seeded on day zero at a concentration enabling continuous log growth over the course of the assay.